Merck-NewLink Ebola vaccine trial resumes at lower dose -Geneva hospital
January 05, 2015 at 07:53 AM EST
GENEVA, Jan 5 (Reuters) - The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said.